Quest Diagnostics Snags Thermo Fisher’s Neuro Testing Lab Biz For $740 Mil.
This article was originally published in The Gray Sheet
Executive Summary
Thermo Fisher Scientific is selling two diagnostic services units, including its Athena Diagnostics neurology testing business, for a total of $940 million, the company announced Feb. 24.
You may also be interested in...
Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q1 2011
For the first three months of 2011, medical device companies raised $733 million, with venture rounds bringing in $494 million. Two-thirds of the $3.9 billion in M&A activity came from Terumo's monstrous $2.6 billion cash takeover of US blood processing equipment maker CaridianBCT Holding. Buoyed by Opko Health's $105 million follow-on, the FOPO category represented almost half of the first quarter's in vitro diagnostics/research $370 million total. The stand-out IVD acquisition was Danaher's $6.8 billion takeover of publicly traded Beckman Coulter.
Quest Highlights Diagnostics Pipeline As Key Component Of Celera Purchase
Quest Diagnostics will expand its molecular diagnostic product offerings and gain a substantial biomarker R&D pipeline while boosting its cardiovascular testing services business through the purchase of Celera for $344 million in cash.
Quest Highlights Diagnostics Pipeline As Key Component Of Celera Purchase
Quest Diagnostics will expand its molecular diagnostic product offerings and gain a substantial biomarker R&D pipeline while boosting its cardiovascular testing services business through the purchase of Celera for $344 million in cash.